Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
Year-end trading update
1 October 2015
Redx Pharma, the drug discovery and development company, today announces a trading update for the financial year ended 30 September 2015.
The Board is pleased to report that Redx has continued to make good progress over the second half of the financial year and that the Group's expenditure remains in line with budgets. Total operating income for the financial year is anticipated to be £2.8 million (six months to 31 March 2015: £2.0 million). The Group's cash balance at the year-end is expected to be approximately £9.4 million.
The Group remains in encouraging discussions with a number of parties regarding further commercial collaborations.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.